“RDCA-DAP’s extensive resources can amplify the impact of the existing data and foster new discoveries in FA research. This collaboration will build upon our strong, sustained, and productive partnership with the C-Path team,” said Farmer.
Thursday, June 20, 2024
C-Path partners with FARA to fortify RDCA-DAP and further accelerate drug development with new Friedreich’s Ataxia Data
TUCSON, Ariz., June 18, 2024 — Critical Path Institute (C-Path), a leader in accelerating drug development for rare diseases, today announced the targeted integration of additional Friedreich’s ataxia (FA) datasets into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) as part of a partnership with Friedreich’s Ataxia Research Alliance (FARA).
